Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome.
Apert syndrome, associated with fibroblast growth factor receptor (FGFR) 2 mutations, is characterized by premature fusion of cranial sutures. We analyzed proliferation and differentiation of calvaria cells derived from Apert infants and fetuses with FGFR-2 mutations. Histological analysis revealed premature ossification, increased extent of subperiosteal bone formation, and alkaline phosphatase- positive preosteoblastic cells in Apert fetal calvaria compared with age-matched controls. Preosteoblastic calvaria cells isolated from Apert infants and fetuses showed normal cell growth in basal conditions or in response to exogenous FGF-2. In contrast, the number of alkaline phosphatase- positive calvaria cells was fourfold higher than normal in mutant fetal calvaria cells with the most frequent Apert FGFR-2 mutation (Ser252Trp), suggesting increased maturation rate of cells in the osteoblastic lineage. Biochemical and Northern blot analyses also showed that the expression of alkaline phosphatase and type 1 collagen were 2-10-fold greater than normal in mutant fetal calvaria cells. The in vitro production of mineralized matrix formed by immortalized mutant fetal calvaria cells cultured in aggregates was also increased markedly compared with control immortalized fetal calvaria cells. The results show that Apert FGFR-2 mutations lead to an increase in the number of precursor cells that enter the osteogenic pathway, leading ultimately to increased subperiosteal bone matrix formation and premature calvaria ossification during fetal development, which establishes a connection between the altered genotype and cellular phenotype in Apert syndromic craniosynostosis.
Lomri
A
A
INSERM U 349, Cell and Molecular Biology of Bone and Cartilage, Lariboisière Hospital, 75475 Paris Cedex 10, France.
Lemonnier
J
J
Hott
M
M
de Parseval
N
N
Lajeunie
E
E
Munnich
A
A
Renier
D
D
Marie
P J
PJ
D000168:Acrocephalosyndactylia / Q000235:genetics* / Q000378:metabolism*; D000469:Alkaline Phosphatase / Q000378:metabolism; D019943:Amino Acid Substitution; D015152:Blotting, Northern; D001857:Bone Matrix / Q000378:metabolism*; D002454:Cell Differentiation / Q000235:genetics; D002455:Cell Division / Q000235:genetics; D002478:Cells, Cultured; D003094:Collagen / Q000378:metabolism; D005333:Fetus / Q000166:cytology / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D015870:Gene Expression; D006651:Histocytochemistry; D006801:Humans; D007223:Infant; D009596:Nitrophenols / Q000378:metabolism; D010012:Osteogenesis / Q000235:genetics; D017354:Point Mutation; D017468:Receptors, Fibroblast Growth Factor / Q000235:genetics* / Q000378:metabolism*; D012694:Serine / Q000235:genetics; D012886:Skull / Q000166:cytology / Q000254:growth & development / Q000378:metabolism*; D014364:Tryptophan / Q000235:genetics
D009596:Nitrophenols; D017468:Receptors, Fibroblast Growth Factor; D016222:Fibroblast Growth Factor 2; D012694:Serine; D014364:Tryptophan; D003094:Collagen; D000469:Alkaline Phosphatase; C024836:4-nitrophenol